stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Return on invested capital
Merck & Co., Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 16.3 percentage points from fiscal 2025 (16.3%). Over the past ten years it has ranged from 2.87% (fiscal 2023) to 18.8% (fiscal 2024); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 6.26% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 16.3% | (2.54) |
| FY2024 | 18.8% | 15.95 |
| FY2023 | 2.87% | (15.68) |
| FY2022 | 18.6% | 4.99 |
| FY2021 | 13.6% | 5.44 |
| FY2020 | 8.12% | (4.82) |
| FY2019 | 12.9% | (1.82) |
| FY2018 | 14.8% | 5.80 |
| FY2017 | 8.96% | 2.12 |
| FY2016 | 6.84% | (1.71) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| ABBV AbbVie Inc. compare | 20.2% |
| AMGN Amgen Inc. compare | 14.3% |
| AZN AstraZeneca PLC compare | 12.3% |
| NVS Novartis AG compare | 12.1% |
| JNJ Johnson & Johnson compare | 11.1% |
| PFE Pfizer Inc. compare | 6.19% |
| MRK Merck & Co., Inc. | 0.00% |
| GILD Gilead Sciences, Inc. compare | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement